Our finding that PR-deficient cells show lower ER levels compared to control cells suggests that the ER+/PR+ breast cancers are more likely to respond to SERM therapy because they could maintain the ESR1 levels higher than breast cancers without PR protein. The gene discussed is PGR; the disease is breast carcinoma.